Hardy Diagnostics Enters Exclusive Partnership with Gradientech
QuickMIC is an ultra-rapid antimicrobial susceptibility testing (AST) system designed to provide critical results for sepsis patients.
This month, Hardy Diagnostics has officially partnered with Gradientech, a Swedish company, to distribute the innovative QuickMIC® system across the US and Canada. This FDA-classified breakthrough device promises to revolutionize how clinicians manage sepsis, providing them with faster and more accurate results.
The Importance of Rapid Testing for Sepsis
The QuickMIC® system plays a vital role in the timely management of sepsis, a severe condition that continues to be a leading cause of morbidity and mortality in healthcare settings. There are significant statistics from health authorities indicating that at least 1.7 million adults in the U.S. are affected by sepsis each year, leading to approximately 250,000 deaths.
Considering the urgency of sepsis treatment, healthcare institutions emphasize the need for actions to be taken within the 'golden hour'—the first hour post-diagnosis. The QuickMIC® system will ensure doctors can make informed antibiotic treatment decisions quickly, thereby improving patient outcomes.
Transforming Hospital Laboratories
Jay Hardy, the President and Founder of Hardy Diagnostics, shared his confidence in this partnership, stating that the QuickMIC® system is poised to become a standard tool in hospital laboratories. "We believe this innovative AST system will not only streamline processes in clinical microbiology but will also be instrumental in saving many lives," he noted.
Clinical Studies and Distribution Plans
The QuickMIC® system is currently in the midst of 510(k) clinical studies at prominent hospitals in North America, while already being utilized in several facilities throughout Europe. As the exclusive distributor for the QuickMIC® system in the US and Canada, Hardy Diagnostics plans to leverage its extensive knowledge of the clinical microbiology landscape to facilitate widespread adoption.
Sara Thorslund, CEO of Gradientech, emphasized their shared vision with Hardy Diagnostics, underscoring the importance of their partnership: "Our two companies align perfectly, valuing our teams and creating synergies that are essential for success in this competitive landscape." This partnership is set to maximize the impact of the QuickMIC® system on patient care.
About Hardy Diagnostics
Hardy Diagnostics is an FDA-licensed manufacturer specializing in medical devices for microbiological testing, with a quality management system ISO 13485 certified. The company produces 2,700 products, distributes over 13,000 products, offers services to more than 10,000 laboratories, and exports to over 80 countries. Their distribution network includes nine centers throughout the United States, enabling them to serve various sectors including clinical, pharmaceutical, and the food and beverage industries.
Company Contact Information
For press inquiries, contact Megan Roesner at (805) 346-2766 x. (5845).
Frequently Asked Questions
What is the QuickMIC® system?
The QuickMIC® system is an ultra-rapid antimicrobial susceptibility testing device intended to help clinicians make informed decisions in the management of sepsis.
How does sepsis impact healthcare?
Sepsis significantly affects patient outcomes and is a leading cause of death in hospitals, highlighting the need for rapid intervention and effective treatment.
Why is this partnership significant?
This exclusive partnership enhances the ability of Hardy Diagnostics to distribute an innovative testing system, increasing access to vital technology in North American healthcare.
What expertise does Hardy Diagnostics bring?
With extensive experience in the clinical microbiology market, Hardy Diagnostics leverages its network and knowledge to support healthcare providers effectively.
How will the QuickMIC® system improve patient care?
By providing rapid and accurate results, the QuickMIC® system allows healthcare professionals to make quicker antibiotic treatment decisions, thereby improving patient outcomes in sepsis management.
